Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF Induction and Reduced Radiation in HPV+ Oropharyngeal Cancer
NCT01221753Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2011
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in squamous cell carcinoma of the oropharynx (OPSCC), sponsored by Dana-Farber Cancer Institute. Started Jul 2011; status: terminated.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the oropharynx (OPSCC)
Beyond the preview
Go deeper on NCT01221753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01221753.